** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business

** The company booked a net profit of 177 million euros ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says

** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg

** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year

** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say

** Share price is at its highest in 1.6 years, outperforming the IBEX35 index .IBEX, which falls 0.6%

($1 = 0.8650 euros)

(Reporting by Mireia Merino)

((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))